Cronos Group
CRONCronos Group Inc. (NASDAQ: CRON | TSX: CRON) is a Canadian cannabinoid company engaged in the research, development, manufacture, and commercialization of cannabis and cannabis-derived products. The company operates in both the consumer and medical markets, with a portfolio that includes dried flower, oils, and vaporizer devices. Its operations span cultivation, processing, and distribution, primarily serving markets in Canada, Israel, and Germany. As a publicly traded entity, Cronos Group is structured to navigate the regulatory frameworks of the jurisdictions in which it operates. The company maintains a research and development focus through its subsidiary, Cronos Group’s R&D division, which investigates the potential applications of cannabinoids. This includes exploration in therapeutic areas such as chronic pain, anxiety, and sleep disorders. Cronos Group has established a multi-year partnership with Ginkgo Bioworks to utilize fermentation technology for the production of cultured cannabinoids, aiming for scalable and consistent ingredient supply for product development. Cronos Group’s strategic activities include brand portfolio management, international medical market distribution, and ongoing scientific research into cannabinoid compounds. The company’s financial and operational performance is subject to the evolving regulatory environments of the cannabis industry in its key markets.
CRON · Stock Price
Historical price data
About
Cronos Group Inc. (NASDAQ: CRON | TSX: CRON) is a Canadian cannabinoid company engaged in the research, development, manufacture, and commercialization of cannabis and cannabis-derived products. The company operates in both the consumer and medical markets, with a portfolio that includes dried flower, oils, and vaporizer devices. Its operations span cultivation, processing, and distribution, primarily serving markets in Canada, Israel, and Germany. As a publicly traded entity, Cronos Group is structured to navigate the regulatory frameworks of the jurisdictions in which it operates. The company maintains a research and development focus through its subsidiary, Cronos Group’s R&D division, which investigates the potential applications of cannabinoids. This includes exploration in therapeutic areas such as chronic pain, anxiety, and sleep disorders. Cronos Group has established a multi-year partnership with Ginkgo Bioworks to utilize fermentation technology for the production of cultured cannabinoids, aiming for scalable and consistent ingredient supply for product development. Cronos Group’s strategic activities include brand portfolio management, international medical market distribution, and ongoing scientific research into cannabinoid compounds. The company’s financial and operational performance is subject to the evolving regulatory environments of the cannabis industry in its key markets.